Towards a Safer, More Randomized Lentiviral Vector Integration Profile Exploring Artificial LEDGF Chimeras

Area of Science:

• Molecular Biology
• Gene Therapy
• Virology

Background:

• Retroviral vectors are valuable for gene therapy but carry risks of insertional mutagenesis, leading to leukemia.
• Lentiviral vector (LV) integration is typically directed to active transcription units by the host protein LEDGF/p75.
• This targeted integration can activate proto-oncogenes, posing a significant safety concern.

Purpose of the Study:

• To engineer novel LEDGF/p75-based hybrid tethers to achieve a more random integration pattern for lentiviral vectors.
• To enhance the biosafety of gene therapy by reducing the risk of proto-oncogene activation.
• To explore the potential of these modified vectors for cell therapy applications.

Main Methods:

• LEDGF/p75 was truncated by deleting its N-terminal PWWP-domain.
• Alternative pan-chromatin binding peptides were used to replace the deleted domain, creating LEDGF-hybrids.
• The efficacy of these LEDGF-hybrids in rescuing LV transduction and directing integration was assessed in LEDGF-depleted cells.

Main Results:

• The engineered LEDGF-hybrids successfully rescued LV transduction in cells lacking endogenous LEDGF/p75.
• LV integrations mediated by LEDGF-hybrids showed a more random distribution throughout the host-cell genome compared to wild-type.
• Integration sites associated with LEDGF-hybrids met safe harbor criteria more effectively than those with native LEDGF/p75.

Conclusions:

• Engineering LEDGF/p75-based hybrid tethers can redirect lentiviral vector integration towards a more random and safer pattern.
• This strategy holds promise for improving the biosafety of gene therapy and reducing insertional mutagenesis risks.
• The approach is potentially applicable for introducing therapeutic or suicide genes in cell therapy, including patient-specific iPS cells.